Daratumumab: all 219 studies that test it

Page 2 of 3. Open to participants first (55), then studies with results posted, then the rest; newest registration first within each.

• Daratumumab for the Treatment of Patients With AL AmyloidosisCompletedNCT02841033Phase 1/2Results posted
• A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple MyelomaActive, not recruitingNCT02773030Phase 1/2Results posted
• A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaCompletedNCT02541383Phase 3Results posted
• An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaTerminatedNCT02413489Phase 2Results posted
• A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple MyelomaCompletedNCT02316106Phase 2Results posted
• Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple MyelomaCompletedNCT02252172Phase 3Results posted
• A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple MyelomaCompletedNCT02195479Phase 3Results posted
• Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02136134Phase 3Results posted
• A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT02076009Phase 3Results posted
• An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiDCompletedNCT01985126Phase 2Results posted
• Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line SettingCompletedNCT01946477Phase 2Results posted
• An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedNCT01592370Phase 1/2Results posted
• Daratumumab (HuMax®-CD38) Safety Study in Multiple MyelomaCompletedNCT00574288Phase 2Results posted
• DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)Active, not recruitingNCT07274462Phase 4
• A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple MyelomaActive, not recruitingNCT06952478Phase 3
• Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)Active, not recruitingNCT06629818Phase 2
• Daratumumab for T Cell ALL With MRD-positive After Standard ChemotherapyWithdrawnNCT06570915Phase 2
• Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell TransplantationWithdrawnNCT06348147Phase 2
• MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaActive, not recruitingNCT06042725Phase 1
• The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal TransplantationStatus unknownNCT05913596Not applicable
• Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple MyelomaActive, not recruitingNCT05849610Phase 2
• Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic AnemiaCompletedNCT05832216Phase 1
• A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male SubjectsCompletedNCT05679258Phase 1
• Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune DepositsActive, not recruitingNCT05654506Phase 2
• A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)TerminatedNCT05641324Phase 1
• Study of Teclistamab in Combination in Elderly Patients With Multiple MyelomaActive, not recruitingNCT05572229Phase 2
• A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune ThrombocytopeniaActive, not recruitingNCT05562882Phase 2
• Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialActive, not recruitingNCT05497804Phase 2
• Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)WithdrawnNCT05486481Phase 1/2
• A Study of DaratumumabActive, not recruitingNCT05438043Phase 3
• Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMMWithdrawnNCT05408026Phase 1/2
• Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT05403138Phase 2/3
• Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyActive, not recruitingNCT05392946Phase 1/2
• A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) AmyloidosisActive, not recruitingNCT05250973Phase 2
• A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple MyelomaCompletedNCT05243342Phase 1
• A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
• FT576 in Subjects With Multiple MyelomaCompletedNCT05182073Phase 1
• A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MMStatus unknownNCT05088330Not applicable
• The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic AnemiaCompletedNCT05004259Phase 1
• Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT04933539Phase 2
• Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in GlioblastomaActive, not recruitingNCT04922723Phase 1/2
• Daratumumab and Pomalidomide in Previously Treated Patients With AL AmyloidosisTerminatedNCT04895917Phase 2
• Daratumumab to Treat Active Lupus NephritisActive, not recruitingNCT04868838Phase 2
• Daratumumab and Belatacept for DesensitizationCompletedNCT04827979Phase 1/2
• An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus ErythematosusStatus unknownNCT04810754Phase 2
• Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04782687Phase 2
• DARA RVD For High Risk SMMActive, not recruitingNCT04775550Phase 2
• The DART Study- Daratumumab Treatment in ITPActive, not recruitingNCT04703621Phase 2
• CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.Active, not recruitingNCT04667663Phase 1
• Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First RelapseActive, not recruitingNCT04656951Phase 2
• A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or LenalidomideActive, not recruitingNCT04497961Phase 2
• Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain AmyloidosisStatus unknownNCT04474938Phase 2
• Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney FailureTerminatedNCT04352205Phase 2
• Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT04280328Phase 1
• Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabActive, not recruitingNCT04270175Phase 2
• A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaActive, not recruitingNCT04268498Phase 2
• Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple MyelomaWithdrawnNCT04230031Phase 2
• Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction TherapyWithdrawnNCT04223661Phase 2
• Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MMActive, not recruitingNCT04176718Phase 2
• Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary DiseaseActive, not recruitingNCT04166565Phase 2
• A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) AmyloidosisCompletedNCT04131309Phase 2
• A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma PatientsActive, not recruitingNCT04124497Phase 2
• A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Phase 1
• A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple MyelomaActive, not recruitingNCT04108195Phase 1
• Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart TransplantationWithdrawnNCT04088903Phase 1
• S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationActive, not recruitingNCT04071457Phase 3
• Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM PatientsCompletedNCT04065789Phase 2
• Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMMCompletedNCT04052880Phase 2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
• Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 TrialWithdrawnNCT04024384Phase 2
• Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMActive, not recruitingNCT04009109Phase 2
• Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positiveStatus unknownNCT03992170Phase 2
• Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-DaraActive, not recruitingNCT03896737Phase 2
• Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaWithdrawnNCT03841565Phase 2
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMAActive, not recruitingNCT03829371Phase 4
• A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory AgentCompletedNCT03768960Phase 4
• Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03763162Phase 2
• Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple MyelomaTerminatedNCT03757221Phase 2
• Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT03746652Phase 2
• Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 YearsActive, not recruitingNCT03742297Phase 3
• Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 DysfunctionActive, not recruitingNCT03734198Phase 2
• Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
• Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple MyelomaStatus unknownNCT03697655Phase 2
• A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT03697629Phase 2
• Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple MyelomaActive, not recruitingNCT03695744Phase 2
• Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaStatus unknownNCT03669445Phase 2
• Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
• An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsActive, not recruitingNCT03606577Phase 2
• Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaWithdrawnNCT03591744Phase 1
• SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaActive, not recruitingNCT03589222Phase 2
• A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell TransplantationActive, not recruitingNCT03556332Phase 2
• Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple MyelomaActive, not recruitingNCT03500445Phase 2
• Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple MyelomaStatus unknownNCT03475628Phase 2
• Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic LeukemiaCompletedNCT03447808Phase 1
• Daratumumab After Stem Cell Transplant in Treating Patients With Multiple MyelomaActive, not recruitingNCT03346135Phase 2
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy ParticipantsCompletedNCT03320707Phase 1
• Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple MyelomaCompletedNCT03311828Phase 1
• Aggressive Smoldering Curative Approach Evaluating Novel Therapies and TransplantActive, not recruitingNCT03289299Phase 2
• Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisCompletedNCT03283917Phase 1
• A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Phase 3

← Daratumumab overview